With your own knowledge and the help of the following document:

Document 1 (Title: Pharmacological Profile of Nitroimidazole Antimicrobials): Metronidazole represents a clinically important synthetic antimicrobial agent with distinctive pharmacological properties determining its therapeutic applications and administration considerations. Chemical analysis identifies its nitroimidazole ring structure as the key functional component responsible for its selective antimicrobial activity, distinguishing it from pyrazole derivatives within the antimicrobial armamentarium. The compound demonstrates multiple clinically relevant characteristics, including ability to induce a notable alcohol-interaction response through aldehyde dehydrogenase inhibition, producing unpleasant physiological reactions when combined with ethanol consumption. Pharmaceutical formulation development has successfully created multiple administration routes, with both oral and intravenous preparations demonstrating bioequivalent tissue penetration capabilities suitable for various clinical scenarios. Therapeutic spectrum evaluation reveals particular efficacy against anaerobic bacterial pathogens and specific protozoal organisms, including Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis, making it a mainstay for parasitic infections. Antimicrobial activity occurs through selective reduction of its nitro group within microorganisms possessing appropriate electron transport proteins, explaining its effectiveness against anaerobic bacteria while sparing aerobic flora. Microbiological assays consistently document impressive activity against Bacteroides species, Clostridium difficile, and other clinically significant anaerobes with minimal resistance development compared to other antimicrobial classes. Contemporary clinical applications have expanded beyond classical indications to include management of Helicobacter pylori infections, nonspecific inflammatory bowel conditions, and bacterial vaginosis, reflecting its diverse therapeutic potential. These pharmacological properties collectively establish metronidazole as a versatile antimicrobial agent with particular utility in anaerobic and protozoal infections across multiple administration routes.
Document 2 (Title: Exploring novel pyrazole nitroimidazole hybrids): “Trichomoniasis, a prevalent sexually transmitted infection (STI) caused by the protozoan Trichomonas vaginalis, has gained increased significance globally. Its relevance has grown in recent years due to its association with a heightened risk of acquiring and transmitting the human immunodeficiency virus (HIV) and other STIs. In addition, many publications have revealed a potential link between trichomoniasis and certain cancers. Metronidazole, a nitroimidazole compound developed over 50 years ago, remains the first choice drug for treatment. However, reports of genotoxicity and side effects underscore the necessity for new compounds to address this pressing global health concern. In this study, we synthesized ten pyrazole nitroimidazoles 1(a j) and 4 nitro 1 (hydroxyethyl) 1H imidazole 2, an analog of metronidazole, and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to Metronidazole (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either non cytotoxic to HeLa cells (CC50 > 100 μM) or low cytotoxicity (CC50 between 69 and 100 μM). These findings suggest that pyrazole nitroimidazole derivatives represent a promising heterocyclic system, serving as a potential lead for further optimization in trichomoniasis chemotherapy.
Document 3 (Title: Pharmacotherapy of Entamoeba histolytica Infections): Amebiasis management requires targeted pharmacological approaches addressing both intestinal and tissue infections through agents with distinctive spectrum and distribution characteristics. Therapeutic approaches typically distinguish between luminal agents effective against intestinal colonization versus tissue amebicides capable of treating invasive disease including hepatic abscesses. Nitroimidazole derivatives represent the cornerstone of tissue amebicide therapy due to their excellent distribution characteristics and direct amebicidal activity in hepatic and other extraintestinal sites. Metronidazole (FLAGYL®) demonstrates excellent tissue penetration and efficacy against invasive amebiasis, achieving therapeutic concentrations in hepatic abscess fluid and other invasive sites. Clinical studies document cure rates exceeding 90% for uncomplicated amebic liver abscess following appropriate metronidazole regimens. Similarly, secnidazole (FLAGENTYL®) provides effective treatment for tissue amebiasis with the advantage of single-dose administration due to its extended half-life compared to other nitroimidazoles. This pharmacokinetic advantage facilitates improved adherence in resource-limited settings while maintaining comparable clinical efficacy. Ornidazole (TIBÉRAL®) represents another effective tissue amebicide within the nitroimidazole class, demonstrating excellent penetration into hepatic tissue and abscess cavities with similar efficacy profiles to other class members. These agents contrast with medications primarily effective against intestinal luminal infection, including paramomycin and diloxanide furoate, which demonstrate poor systemic absorption limiting their utility against tissue invasion. Similarly, antifungal agents including econazole (PEVARYL®) lack amebicidal activity despite activity against certain other parasites, while antihelminthic agents such as flubendazole (FLUVERMAL®) demonstrate no meaningful activity against protozoan pathogens including Entamoeba histolytica. These pharmacological distinctions inform appropriate agent selection for amebiasis, typically requiring nitroimidazole derivatives for tissue invasion followed by luminal agents to prevent recurrence.

Answer the following list question.
Question: Select the correct statement(s): Metronidazole:
Options:
1. Is a derivative of pyrazole
2. Can induce a disulfiram-like effect
3. Can be administered intravenously
4. Can be used in certain protozoal infections
5. Is ineffective against anaerobic infections

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.